Ablynx extends ion channel research collaboration with Merck & Co.

27-Mar-2015 - Belgium

Ablynx announced an extension of its initial two-year research collaboration with Merck & Co., Inc., known as MSD outside the United States and Canada, to develop and commercialise Nanobody® candidates directed towards an undisclosed voltage gated ion channel.

Merck & Co., Inc. will extend their funding of the research collaboration with Ablynx to the end of September 2016. This ion channel collaboration was announced in October 2012 and included a €6.5 million upfront payment and €2 million in initial research funding.

Merck and Ablynx have a separate collaboration in the field of cancer immuno-therapy, announced in February in 2014, with a €20 million upfront payment, €10.7 million in research funding and total potential milestone payments of up to €1.7 billion plus royalties.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...